Benign call rate and molecular test result distribution of ThyroSeq v3

Background The benign call rate (BCR) is the percentage of cytomorphologically indeterminate cases with subsequent benign or negative molecular results. For rule‐out tests, the BCR is an important parameter because these molecular “negative” cases may be managed similarly to those with a benign cytology diagnosis. Although earlier versions of ThyroSeq molecular tests were less effective in excluding malignancy, the extensively expanded v3...